Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control

References

• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229–34
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421
   Google Scholar
• Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a ‘coronary heart disease equivalent’: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28: 2901–7
   Google Scholar
• Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69–75
   PubMed Web of Science ®Google Scholar
• Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001;24:1422–7
   PubMed Web of Science ®Google Scholar
• Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract 2006;60:48–56
   Google Scholar
• Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093–100
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854–65
   Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–9
   Google Scholar
• Prisant LM. Clinical trials and lipid guidelines for type II diabetes. J Clin Pharmacol 2004;44:423–30
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. REVIEW: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006;91:383–92
   PubMed Web of Science ®Google Scholar
• Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257–62
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823–8
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Pogue J, Mann JF, et al.; HOPE investigators. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005;48:1749–55
   Google Scholar
• Stratton IM, Adler AI, Neil AW, et al.; on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321: 405–12
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317: 703–13
   Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353: 2643–53
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733–49
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al.; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104;1108–13
   Google Scholar
• Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006 Mar 27; [Epub ahead of print]
   Google Scholar
• Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004;109:1112–7
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364: 685–96
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS Investigators. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005;48:2482–5
   Google Scholar
• Gmerek A, McLain R, Nawrocki J. A 4-year, placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin-dependent diabetes mellitus. Diabetes 1997;46:363A
   Google Scholar
• Pyörälä K, Pedersen TR, Kjekshus J, et al.; for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20: 614–20
   Google Scholar
• Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661–7
   Google Scholar
• Pyörälä K, Ballantyne CM, Gumbiner B, et al.; Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004;27: 1735–40
   Google Scholar
• Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM, et al.; for the Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513–9
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16
   PubMed Web of Science ®Google Scholar
• Shepherd J, LaRosa JC, Waters DD. Intensive lipid-lowering with atorvastatin in patients with diabetes and stable coronary disease. Late-breaking abstract. Presented at the American Diabetes Association 65th Scientific Sessions, San Diego CA, June 10–14, 2005
   Google Scholar
• Deedwania PC, Shepherd J, Barter P, et al.; on behalf of the TNT Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with metabolic syndrome and stable coronary disease. Circulation 2005;112:662
   Google Scholar
• Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–62
   Google Scholar
• Skyler JS. Effects of glycemic control on diabetes complications and on the prevention of diabetes. Clin Diabetes 2004;22:162–6
   Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators 2005. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352: 20–8
   Google Scholar
• Rubins HB, Robins SJ, Collins D, et al.; for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–8
   Google Scholar
• Robins SJ, Rubins HB, Faas FH, et al.; Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513–7
   Google Scholar
• Koskinen P, Mänttäri M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820–5
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366: 1849–61
   Google Scholar
• Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–81
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, et al.; for the Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–55
   Google Scholar
• Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723–6
   PubMed Web of Science ®Google Scholar
• Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492–9
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203–7
   PubMed Web of Science ®Google Scholar
• Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121–34
   Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28: 1547–54
   Google Scholar
• Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005;6:7–14
   PubMed Web of Science ®Google Scholar
• Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89: 463–78
   Google Scholar
• Pilz S, Scharnagl H, Tiran B, et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab 2006;91:2542–7
   PubMed Web of Science ®Google Scholar
• Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000;35:1038–42
   PubMed Web of Science ®Google Scholar
• Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study. Circulation 1997;96:4239–45
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317: 713–20
   Google Scholar
• The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2981–97
   PubMed Web of Science ®Google Scholar
• Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab 2005;19:567–75
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004;30: 487–96
   Google Scholar
• Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006;55:1133–40
   PubMed Web of Science ®Google Scholar
• Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813–23
   PubMed Web of Science ®Google Scholar
• Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971–7
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65
   PubMed Web of Science ®Google Scholar
• Soinio M, Marniemi J, Laakso M, et al. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006;29:329–33
   PubMed Web of Science ®Google Scholar
• de Jager J, Dekker JM, Kooy A, et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes. The Hoorn Study. Arterioscler Thromb Vasc Biol 2006;26:1086–93
   PubMed Web of Science ®Google Scholar
• Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1–31
   PubMed Web of Science ®Google Scholar
• Tayebjee M, Lim H, MacFadyen R, et al. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes mellitus: effect of one year’s cardiovascular risk reduction therapy. Diabetes Care 2004;27:2049–51
   PubMed Web of Science ®Google Scholar
• Song W, Ergul A. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol 2006;5:3
   PubMed Web of Science ®Google Scholar
• Shaw SG, Boden PJ. Insulin resistance, obesity and the metabolic syndrome. Is there a therapeutic role for endothelin-1 antagonists? Curr Vasc Pharmacol 2005;3: 359–63
   Google Scholar
• Kyriakides ZS, Kremastinos DT, Raptis AE, et al. Impaired effect of endothelin-1 on coronary artery stiffness in type 2 diabetes. Int J Cardiol 2005 Dec 1; [Epub ahead of print]
   Google Scholar
• Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432–7
   PubMed Web of Science ®Google Scholar
• Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997;28:2442–7
   Google Scholar
• Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 1997;146:483–94
   PubMed Web of Science ®Google Scholar
• Wagenknecht LE, D’Agostino R Jr, Savage PJ, et al. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997;28:999–1005
   Google Scholar
• Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, et al. Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care 1999;22: 333–8
   Google Scholar
• Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol 2002;155:38–47
   PubMed Web of Science ®Google Scholar
• Wagenknecht LE, Zaccaro D, Espeland MA, et al. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003;23:1035–41
   PubMed Web of Science ®Google Scholar
• Howard G, O’Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809–17
   Google Scholar
• Bonora E, Tessari R, Micciolo R, et al. Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Relationship with insulin resistance. Diabetes Care 1997;20:627–31
   PubMed Web of Science ®Google Scholar
• Mangrum A, Bakris GL. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications 1997;11:352–7
   PubMed Web of Science ®Google Scholar
• Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol 2004;286:F442–50
   PubMed Web of Science ®Google Scholar
• Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin 2005; 21:S5–12
   PubMed Web of Science ®Google Scholar
• Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3–9
   PubMed Web of Science ®Google Scholar
• Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213–21
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al.; for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62
   Google Scholar
• Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005;293:1501–8
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following PCI. J Am Coll Cardiol 2000;35:922–8
   PubMed Web of Science ®Google Scholar
• Sobel BE, Frye R, Detre KM; Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003;107: 636–42
   Google Scholar
• Campbell IW. Pioglitazone – an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice? Br J Diabetes Vasc Dis 2005:209–16
   Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279–89
   Google Scholar
• European Diabetes Policy Group 1998–1999. A desktop guide to type 2 diabetes mellitus. Available from http://www.staff.ncl.ac.uk/philip.home/t2dgw97r.doc [Last accessed 22 March 2006]
   Google Scholar
• Erdmann E. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive study. Presentation at the American Heart Association. Available from http://www.proactive-results.com/ahappt/AHA_files/frame. htm [Last accessed 19 April 2006]
   Google Scholar
• Home PD, Komajda M, Beck-Nielsen H, et al. Twelve months sustained efficacy of rosiglitazone combination therapy on ambulatory blood pressure (ABP) in people with type 2 diabetes mellitus. Diabetes 2005;54:A143
   Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726–35
   Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93
   PubMed Web of Science ®Google Scholar